DPHARMA

Quarterly rpt on consolidated results for the financial period ended 31 Dec 2017

Amended Announcements
Please refer to the earlier announcement reference number: FRA-25022018-00004

CCM DUOPHARMA BIOTECH BERHAD

Financial Year End 31 Dec 2017
Quarter 4 Qtr
Quarterly report for the financial period ended 31 Dec 2017
The figures have not been audited

Attachments

CCMD - Q42017.pdf
447.3 kB


Remarks : 
Amendments have been made to columns 1 to 4 of item no. 6 of Part A2: Summary of Key Financial Information in respect of the Proposed/Declared dividend per share (Subunit). An amendment has also been made in respect of Note B10 (a) in relation to the comparative reference to the final dividend for 2016, on Page 4 of 5 of the Notes to Interim Financial Report for the Quarterly Report on Results for the Financial Year Ended 31 December 2017, as attached.

As announced by the Company on 27 February 2018 prior to the announcement of the Quarterly Report for the financial period ended 31 December 2017, for the current financial year ended 31 December 2017, the Board of Directors recommends a final dividend of 6 sen per share (2016: a final dividend of 4 sen per share). The final dividend is subject to shareholders' approval at the Annual General Meeting (AGM) of the Company. The total dividend for the current financial year ended 31 December 2017 is 8.5 sen per share comprising of a final dividend of 6 sen and an interim dividend of 2.5 sen.

The total dividend for preceding year corresponding period in respect of financial year ended 31 December 2016 was an Interim Dividend of 2.5 sen per share that was paid on 11 November 2016 and a final dividend of 4 sen per share that was paid on 23 June 2017.
  • Default Currency
  • Other Currency

Currency: Malaysian Ringgit (MYR)

SUMMARY OF KEY FINANCIAL INFORMATION
31 Dec 2017

 
INDIVIDUAL PERIOD
CUMULATIVE PERIOD
CURRENT YEAR QUARTER
PRECEDING YEAR
CORRESPONDING
QUARTER
CURRENT YEAR TO DATE
PRECEDING YEAR
CORRESPONDING
PERIOD
31 Dec 2017
31 Dec 2016
31 Dec 2017
31 Dec 2016
$$'000
$$'000
$$'000
$$'000
1 Revenue
112,253
74,033
467,987
312,940
2 Profit/(loss) before tax
12,825
6,299
51,796
31,479
3 Profit/(loss) for the period
11,768
8,831
42,100
26,826
4 Profit/(loss) attributable to ordinary equity holders of the parent
11,870
8,428
42,492
27,115
5 Basic earnings/(loss) per share (Subunit)
4.22
3.41
15.09
9.62
6 Proposed/Declared dividend per share (Subunit)
6.00
4.00
8.50
6.50


AS AT END OF CURRENT QUARTER
AS AT PRECEDING FINANCIAL YEAR END
7
 Net assets per share attributable to ordinary equity holders of the parent ($$)
1.7200
1.6300

Remarks : 
As announced by the Company on 27 February 2018 prior to the announcement of the Quarterly Report for the financial period ended 31 December 2017, for the current financial year ended 31 December 2017, the Board of Directors recommends a final dividend of 6 sen per share (2016: a final dividend of 4 sen per share). The final dividend is subject to shareholders' approval at the Annual General Meeting (AGM) of the Company. The total dividend for the current financial year ended 31 December 2017 is 8.5 sen per share comprising of a final dividend of 6 sen and an interim dividend of 2.5 sen.

The total dividend for preceding year corresponding period in respect of financial year ended 31 December 2016 was an Interim Dividend of 2.5 sen per share that was paid on 11 November 2016 and a final dividend of 4 sen per share that was paid on 23 June 2017.

Definition of Subunit:

In a currency system, there is usually a main unit (base) and subunit that is a fraction amount of the main unit.
Example for the subunit as follows:

Country Base Unit Subunit
Malaysia Ringgit Sen
United States Dollar Cent
United Kingdom Pound Pence



Announcement Info

Company Name CCM DUOPHARMA BIOTECH BERHAD
Stock Name CCMDBIO
Date Announced 28 Feb 2018
Category Financial Results
Reference Number FRA-28022018-00004


View original report